

Significant and Sustained Pain Relief: COMFORT PNS RCT at 1-year

Authors: M. Engle¹, J. Hatheway², A. Hersel³, G. Gutierrez⁴, V. Khemlani⁵, L. Kapural⁶, G. Moore⁷, R. Ajakwe⁸, D. Trainor⁹, JM Hah¹⁰, S. Kottalgi¹¹; MJ Desai¹²

Affiliations: ¹Institute of Precision Pain Medicine, TX; ²Northwest Pain Care, WA; ³Pain Relief & Injury Management, CA; ⁴Pain Specialists of America, TX; ⁵Columbia Pain Management, OR; ⁶Carolinas Pain Institute, NC; ⁷Pacific Sports and Spine, OR; ⁸Comprehensive Spine & Pain Physicians, CA; ⁹DBPS Research, LLC; ¹⁰Stanford Medicine, CA; ¹¹Nalu Medical, Inc., Carlsbad, CA; ¹²International Spine, Pain & Performance Center, DC.

Introduction

We are reporting 1 year data from the COMFORT randomized clinical trial (for details see QR code) involving a micro-implantable pulse generator (micro-IPG) system (Nalu Medical Inc., Carlsbad, CA).



Methods

Subjects in the COMFORT study were randomized to either the Active arm (PNS with conventional medical management (CMM) or the Control Arm (CMM alone). Control Arm subjects could cross over to Active at 3-months. Subjects needed to have a successful trial ($\geq 50\%$ pain relief from baseline) lasting 7-10 days to receive the permanent implant. Subjects will be followed out to 36 months at various timepoints. 47 subjects completed 1-year follow-up and the results are reported here.



Results

- PNS with CMM was superior to CMM alone, meeting the primary endpoint.
 - At 3-months the Active Arm had an 81% responder rate compared to 3% for the Control Arm ($p < 0.001$).¹
 - At 1 year the responder rate was 87% with an 70% average pain reduction.
- The trial success rate of 91% accurately predicted responders with low rate of false positives, demonstrating no need for protracted trial periods.
- A majority of subjects achieved Minimal Clinically Important Difference (MCID) for the various functional outcomes.^{2,3}
- Majority of subjects were programmed with specific complex programming delivered by the micro-IPG including multi-area, multi-contact, high pulse width and high frequency programs and scheduled programs.⁴

Individual pain relief at 1-year



Timepoint	1-month	3-months	6-months	9-months	12-months
Mean Pain Relief (%)	58%	65%	69%	67%	70%
Responder Rate ($\geq 50\%$)	74%	81%	82%	75%	87%



Conclusions

- Significant and sustained pain relief out to 1-year
- No serious adverse device effects or reports of pocket pain
- MCID for functional outcomes achieved by majority of subjects.

References

1. Hatheway J, Hersel A, Song J, et al. Reg Anesth Pain Med Epub 2024;0:1-7. doi:10.1136/rapm-2023-105264.
2. Ostelo RW, de Vet HC. Best Pract Res Clin Rheumatol. 2005. 19:593-607.
3. Dworkin RH, Turk DC, Wyrwich KW et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008 Feb;9(2):105-121.
4. M. Engle et al. Complex programming yields beneficial outcomes in COMFORT PNS RCT. ePoster ASPN 2024



Scan for detailed information about the COMFORT study